TSS
MNPR icon

Two Sigma Securities’s Monopar Therapeutics MNPR Stock Holding History

Two Sigma Securities’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,412
Closed -$34.4K – 3350
2024
Q2 		$34.4K Buy
+9,412
New +$33.1K ﹤0.01% 2624
2023
Q4 		– Sell
-4,933
Closed -$15.3K – 3382
2023
Q3 		$15.3K Buy
+4,933
New +$17.2K ﹤0.01% 2619

Other funds holding MNPR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's MNPR Position: Q3 2024 in Review

Two Sigma Securities sold out of Monopar Therapeutics (MNPR) in Q3 2024, closing a stake of 9,412 shares — an estimated $34.4K sold.

Two Sigma Securities first reported a position in MNPR in Q3 2023 and held it in 2 quarters. The position peaked at $34.4K in Q2 2024. 6 funds tracked by Wall St. Rank hold MNPR as of Q3 2024.

  • Two Sigma Securities reported no remaining Monopar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Securities sold 9,412 Monopar Therapeutics shares in Q3 2024, an estimated $34.4K.
  • Two Sigma Securities first reported a position in Monopar Therapeutics in Q3 2023 and held it in 2 quarters.
  • Two Sigma Securities's Monopar Therapeutics position peaked at $34.4K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.